Pathway of MHC Class I Presentation of Soluble Antigens by DC
| Treatment* . | Antigen . | % Specific Lysis at E:T . | ||
|---|---|---|---|---|
| . | . | 10 . | 3 . | 1 . |
| — | — | 5 | 2 | 1 |
| OVA-peptide | 76 | 56 | 32 | |
| OVA-protein | 48 | 28 | 14 | |
| Amiloride | — | 7 | 3 | 0 |
| OVA-peptide | 70 | 52 | 28 | |
| OVA-protein | 12 | 4 | 0 | |
| Brefeldin A | — | 4 | 5 | 0 |
| OVA-peptide | 73 | 54 | 26 | |
| OVA-protein | 10 | 4 | 2 | |
| LLnL | — | 7 | 1 | 4 |
| OVA-peptide | 72 | 52 | 31 | |
| OVA-protein | 6 | 5 | 3 | |
| LLM | — | 6 | 1 | 0 |
| OVA-peptide | 78 | 54 | 29 | |
| OVA-protein | 31 | 15 | 6 | |
| Chloroquine | — | 5 | 0 | 2 |
| OVA-peptide | 69 | 49 | 26 | |
| OVA-protein | 47 | 30 | 10 | |
| Treatment* . | Antigen . | % Specific Lysis at E:T . | ||
|---|---|---|---|---|
| . | . | 10 . | 3 . | 1 . |
| — | — | 5 | 2 | 1 |
| OVA-peptide | 76 | 56 | 32 | |
| OVA-protein | 48 | 28 | 14 | |
| Amiloride | — | 7 | 3 | 0 |
| OVA-peptide | 70 | 52 | 28 | |
| OVA-protein | 12 | 4 | 0 | |
| Brefeldin A | — | 4 | 5 | 0 |
| OVA-peptide | 73 | 54 | 26 | |
| OVA-protein | 10 | 4 | 2 | |
| LLnL | — | 7 | 1 | 4 |
| OVA-peptide | 72 | 52 | 31 | |
| OVA-protein | 6 | 5 | 3 | |
| LLM | — | 6 | 1 | 0 |
| OVA-peptide | 78 | 54 | 29 | |
| OVA-protein | 31 | 15 | 6 | |
| Chloroquine | — | 5 | 0 | 2 |
| OVA-peptide | 69 | 49 | 26 | |
| OVA-protein | 47 | 30 | 10 | |
bmDC were incubated with 20 ng/mL GM-CSF and 2 mg/mL ovalbumin in the presence or absence of 50 μmol/L amiloride or 5 μg/mL brefeldin A or 50 μmol/L LLnL or LLM or chlorquine. Inhibitors were added to cell medium 30 minutes before incubation with ovalbumin and were present during the chase period of 3 hours. Lysis of bmDC pulsed with OVA peptide (1 μmol/L) or OVA protein (2 mg/mL) by OVA-specific CTL clone B3 was assessed in a standard 51Cr-release assay.